Related references
Note: Only part of the references are listed.Identification of Carboxylesterase-Dependent Dabigatran Etexilate Hydrolysis
S. Casey Laizure et al.
DRUG METABOLISM AND DISPOSITION (2014)
Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism
Zhe-Yi Hu et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2013)
Oral bioavailability of dabigatran etexilate (Pradaxa®) after co-medication with verapamil in healthy subjects
Sebastian Haertter et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin
Xavier Delavenne et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Disposition Pathway-Dependent Approach for Predicting Organic Anion-Transporting Polypeptide-Mediated Drug-Drug Interactions
Zhe-Yi Hu
CLINICAL PHARMACOKINETICS (2013)
Application of Permeability-Limited Physiologically-Based Pharmacokinetic Models: Part I-Digoxin Pharmacokinetics Incorporating P-Glycoprotein-Mediated Efflux
Sibylle Neuhoff et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Application of Permeability-Limited Physiologically-Based Pharmacokinetic Models: Part II - Prediction of P-Glycoprotein Mediated Drug-Drug Interactions with Digoxin
Sibylle Neuhoff et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Dabigatran and Postmarketing Reports of Bleeding
Mary Ross Southworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria
Joe Bentz et al.
DRUG METABOLISM AND DISPOSITION (2013)
Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions
Harma Ellens et al.
DRUG METABOLISM AND DISPOSITION (2013)
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin
Sebastian Haertter et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Absence of Pharmacokinetic Interaction Between Roflumilast and Digoxin in Healthy Adults
Gabriel Eckermann et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, With Coadministration of Digoxin
Joachim Stangier et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: Extension to describe performance of solid dosage forms
Kirstin Thelen et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
In Vivo Information-Guided Prediction Approach for Assessing the Risks of Drug-Drug Interactions Associated with Circulating Inhibitory Metabolites
Zhe-Yi Hu et al.
DRUG METABOLISM AND DISPOSITION (2012)
Using Expression Data for Quantification of Active Processes in Physiologically Based Pharmacokinetic Modeling
Michaela Meyer et al.
DRUG METABOLISM AND DISPOSITION (2012)
Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review
P. Zhao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Evolution of a Detailed Physiological Model to Simulate the Gastrointestinal Transit and Absorption Process in Humans, Part 1: Oral Solutions
Kirstin Thelen et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Drug-Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro-In Vivo Correlation Using Digoxin as a Probe Drug
K. S. Fenner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers
Tomonori Tateishi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
Joachim Stangier
CLINICAL PHARMACOKINETICS (2008)
Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment
Joachim Stangier et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P-Glycoprotein in the Disposition of Aliskiren
Sujata Vaidyanathan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
Stefan Blech et al.
DRUG METABOLISM AND DISPOSITION (2008)
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
Joachim Stangier et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man
Erica L. Bradshaw-Pierce et al.
CLINICAL CANCER RESEARCH (2007)
Mechanistic approaches to volume of distribution predictions: Understanding the processes
Trudy Rodgers et al.
PHARMACEUTICAL RESEARCH (2007)
Mechanistic modeling of digoxin distribution kinetics incorporating slow tissue binding
Michael Weiss
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2007)
Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein
Mikiko Shimizu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Time-dependent interaction between lopinavir/ritonavir and fexofenadine
Rolf P. G. van Heeswijk et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
Trudy Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases
T Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics
N Yasui-Furukori et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers
R Ding et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition
C Verstuyft et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Effect of grapefruit juice on digoxin pharmacokinetics in humans
L Becquemont et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein
K Westphal et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
